MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$176,243K
Net Income
-$67,227K
Net Profit Margin
-38.14%
EPS
-$1.06
Unit: Thousand (K) dollars
Revenue Breakdown
Livmarli
Bile Acid Medicines
Revenue Breakdown
US
Non Us
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product sales, net
176,243
159,882
148,932
133,010
Cost of sales
30,348
28,805
28,264
25,537
Research and development
90,528
97,910
51,107
42,960
Acquired in-process research and development
16,435
726,302
-
-
Selling, general and administrative
81,469
96,330
74,128
61,910
Total operating expenses
218,780
949,347
153,499
130,407
Loss from operations
-42,537
-789,465
-4,567
2,603
Interest income
3,851
3,401
3,420
3,251
Interest expense
2,618
3,616
3,598
3,606
Loss from termination of revenue interest purchase agreement
-
-
0
-
Other (expense) income, net
-24,234
0
-218
395
Net loss before provision for income taxes
-65,538
-789,680
-4,963
2,643
Provision for income taxes
1,689
475
767
-262
Net loss
-67,227
-790,155
-5,730
2,905
Basic EPS
-1.06
-13.43
-0.111
0.06
Diluted EPS
-1.06
-13.43
-0.127
0.05
Basic Average Shares
63,374,183
58,851,021
51,538,104
50,639,231
Diluted Average Shares
63,374,183
58,851,021
45,183,494
56,993,841
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
-$67,227K
(-1047.02%↓ Y/Y)
Net loss before
provision for income taxes
-$65,538K
(-1100.55%↓ Y/Y)
Provision for income taxes
$1,689K
(320.15%↑ Y/Y)
Interest income
$3,851K
(26.97%↑ Y/Y)
Livmarli
$128,721K
(46.01%↑ Y/Y)
Bile Acid Medicines
$47,522K
(19.93%↑ Y/Y)
Loss from operations
-$42,537K
(-752.62%↓ Y/Y)
Other (expense)
income, net
-$24,234K
(-28279.07%↓ Y/Y)
Product sales, net
$176,243K
(37.92%↑ Y/Y)
Interest expense
$2,618K
(-27.05%↓ Y/Y)
Total operating
expenses
$218,780K
(64.78%↑ Y/Y)
Research and development
$90,528K
(96.51%↑ Y/Y)
Selling, general and
administrative
$81,469K
(28.73%↑ Y/Y)
Cost of sales
$30,348K
(29.58%↑ Y/Y)
Acquired in-process
research and development
$16,435K
Buy us a coffee
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)